We have located links that may give you full text access.
Safety and Efficacy of Praziquantel in Pregnant Women Infected with Schistosoma haematobium in Lambaréné, Gabon - Clinical Results from the Randomized, Single-Blinded, Controlled freeBILy-Gabon Trial.
International Journal of Infectious Diseases : IJID 2024 October 3
OBJECTIVE: Despite evidence of praziquantel's safety for treating schistosomiasis in pregnancy, many countries withhold treatment. Only two randomized controlled trials have investigated praziquantel in pregnancy, none involving Schistosoma haematobium.
METHODS: Pregnant women during second trimester in Lambaréné (Gabon) were screened for S. haematobium infection using urine microscopy and circulating anodic antigen detection. Participants positive for either test were randomized (3:1) to single-dose praziquantel 40mg/kg during pregnancy versus no treatment during pregnancy. Investigators were blinded for allocation. Primary outcomes were reduction of egg- (ERR) and antigen production (IRR) while explorative outcomes included assessment of cure rate, adverse events, maternal hemoglobin levels maternal anemia prevalence at delivery, pregnancy outcomes, and newborn anthropometric parameters.
RESULTS: Of 761 women screened 165 were eligible and randomized (intervention n=124, control n=41). 124 completed the study (n=90 and n=34, respectively). Tretament led to a significant higher ERR (95.0%[91%-97%] vs. 27.0%[-42%-63%]) and IRR (95%[91%-97%] vs. 56%[14%-78%]). Common adverse events were dizziness, nausea, and vomiting. Maternal anemia at delivery was significantly lower in the intervention group (OR:0.40[0.16;0.96],p=0.04). No increased risk for adverse pregnancy outcomes was observed.
CONCLUSIONS: This first randomized controlled trial investigating praziquantel in pregnant women with S. haematobium found praziquantel to be safe, effective and reducing maternal anemia. We recommend treating confirmed infections to prevent morbidity in pregnant women.
METHODS: Pregnant women during second trimester in Lambaréné (Gabon) were screened for S. haematobium infection using urine microscopy and circulating anodic antigen detection. Participants positive for either test were randomized (3:1) to single-dose praziquantel 40mg/kg during pregnancy versus no treatment during pregnancy. Investigators were blinded for allocation. Primary outcomes were reduction of egg- (ERR) and antigen production (IRR) while explorative outcomes included assessment of cure rate, adverse events, maternal hemoglobin levels maternal anemia prevalence at delivery, pregnancy outcomes, and newborn anthropometric parameters.
RESULTS: Of 761 women screened 165 were eligible and randomized (intervention n=124, control n=41). 124 completed the study (n=90 and n=34, respectively). Tretament led to a significant higher ERR (95.0%[91%-97%] vs. 27.0%[-42%-63%]) and IRR (95%[91%-97%] vs. 56%[14%-78%]). Common adverse events were dizziness, nausea, and vomiting. Maternal anemia at delivery was significantly lower in the intervention group (OR:0.40[0.16;0.96],p=0.04). No increased risk for adverse pregnancy outcomes was observed.
CONCLUSIONS: This first randomized controlled trial investigating praziquantel in pregnant women with S. haematobium found praziquantel to be safe, effective and reducing maternal anemia. We recommend treating confirmed infections to prevent morbidity in pregnant women.
Full text links
Related Resources
Trending Papers
2024 Guideline for the Primary Prevention of Stroke: A Guideline From the American Heart Association/American Stroke Association.Stroke; a Journal of Cerebral Circulation 2024 October 21
Paroxysmal Nocturnal Hemoglobinuria, Pathophysiology, Diagnostics, and Treatment.Transfusion Medicine and Hemotherapy 2024 October
The Role of Natriuretic Peptides in the Management of Heart Failure with a Focus on the Patient with Diabetes.Journal of Clinical Medicine 2024 October 18
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app